abbvie_0

Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack

pharmafile | March 27, 2018 | News story | Manufacturing and Production, Sales and Marketing AbbVie, Endo, GSK, androgel, heart attack, pharma 

Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of the company’s testosterone replacement drug AndroGel drove him to a heart attack, a risk which he argues was vastly misrepresented.

Jesse Mitchell of Oregon had been using the therapy for five years before suffering the attack in 2012. While the jury concluded that Abbvie had not intentionally misrepresented the product in its marketing, it judged that the company had acted negligently, with the court awarding Mitchell £200,000 in compensatory damages and $3 million in punitive damages. Abbvie has said that it plans to appeal the decision.

Earlier, the Chicago-based firm was forced to pay out $140 million to a Tennessee resident who also claimed that the use of AndroGel led to a heart attack. Abbvie has requested that the verdict be thrown out, citing inconsistencies throughout the trial.

Advertisement

Over 6,000 similar cases are currently filed against a range of drugmakers including Eli Lilly, Endo International and GlaxoSmithKline over the use of testosterone replacement products, though more than 4,000 of these are levied against Abbvie. In the past months, GSK and Lilly have reportedly agreed to settle hundreds of these lawsuits, thought the details of these settlements are unknown.  

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Multiple myeloma treatment approved in Japan

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

The Gateway to Local Adoption Series

Latest content